Bharmal Murtuza, Marrel Alexia, Hennessy Meliessa, Fofana Fatoumata, Lambert Jérémy, Arnould Benoit
Merck KGaA, Darmstadt, Germany.
Mapi, an Icon plc company, Patient-Centered Outcomes, Lyon, France.
J Comp Eff Res. 2018 Sep;7(9):881-890. doi: 10.2217/cer-2018-0048. Epub 2018 Aug 15.
To assess patient experience with chemotherapy and avelumab in metastatic Merkel cell carcinoma (mMCC).
In the JAVELIN Merkel 200 trial, chemotherapy-refractory mMCC patients could participate in optional qualitative interviews at baseline documenting recollection of previous chemotherapy experience, and at weeks 13/25 documenting current experience with avelumab. Functional Assessment of Cancer Therapy subscale for melanoma questionnaire (FACT-M) was administered in parallel.
In our sample, chemotherapy was associated with an unpleasant experience. On selected FACT-M items addressing chemotherapy-impacted concepts, most patients receiving avelumab were improved or stable; few worsened. In addition, a few patients spontaneously reported experiencing less toxicity with avelumab than experienced during previous chemotherapy.
This approach merging qualitative and quantitative data suggests that mMCC patients report a better experience with avelumab than with chemotherapy.
评估转移性默克尔细胞癌（mMCC）患者接受化疗和阿维鲁单抗的体验。
在JAVELIN Merkel 200试验中，化疗难治性mMCC患者可在基线时参与可选的定性访谈，记录对既往化疗经历的回忆，并在第13/25周记录当前使用阿维鲁单抗的体验。同时并行开展癌症治疗功能评估黑色素瘤问卷（FACT-M）。
在我们的样本中，化疗与不愉快的体验相关。在选定的涉及化疗影响概念的FACT-M项目中，大多数接受阿维鲁单抗治疗的患者情况改善或稳定；少数患者情况恶化。此外，少数患者自发报告称，与既往化疗相比，使用阿维鲁单抗时的毒性更小。
这种将定性和定量数据相结合的方法表明，mMCC患者使用阿维鲁单抗的体验优于化疗。
